ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
reader1
|
350 |
143K |
2 |
04/05/17 |
04/05/17 |
ASX - By Stock
|
350
|
143K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
reader1
|
350 |
143K |
3 |
04/05/17 |
04/05/17 |
ASX - By Stock
|
350
|
143K
|
3
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
reader1
|
350 |
143K |
3 |
04/05/17 |
04/05/17 |
ASX - By Stock
|
350
|
143K
|
3
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
reader1
|
350 |
143K |
9 |
04/05/17 |
04/05/17 |
ASX - By Stock
|
350
|
143K
|
9
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
reader1
|
350 |
143K |
20 |
04/05/17 |
04/05/17 |
ASX - By Stock
|
350
|
143K
|
20
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Receives FDA Clearance for CardioCel 3D
|
|
reader1
|
134 |
51K |
12 |
02/05/17 |
02/05/17 |
ASX - By Stock
|
134
|
51K
|
12
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
reader1
|
296 |
158K |
6 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
6
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
reader1
|
296 |
158K |
12 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
12
|
|
ASX - By Stock
|
TSO |
Re:
Ann: Quarterly Update and Appendix 4C
|
|
reader1
|
6 |
4.1K |
2 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
6
|
4.1K
|
2
|
|
ASX - By Stock
|
VFX |
Re:
Ann: 1ST Group reaches 5 million bookings milestone
|
|
reader1
|
5 |
2.3K |
0 |
06/03/17 |
06/03/17 |
ASX - By Stock
|
5
|
2.3K
|
0
|
|
ASX - By Stock
|
TSO |
Re:
News: PKA Plukka enters into financing agreement with Treliss Worldwide Inc
|
|
reader1
|
1 |
1.0K |
2 |
06/03/17 |
06/03/17 |
ASX - By Stock
|
1
|
1.0K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Initial Director's Interest Notice
|
|
reader1
|
36 |
10K |
1 |
23/02/17 |
23/02/17 |
ASX - By Stock
|
36
|
10K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Initial Director's Interest Notice
|
|
reader1
|
36 |
10K |
2 |
23/02/17 |
23/02/17 |
ASX - By Stock
|
36
|
10K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Initial Director's Interest Notice
|
|
reader1
|
36 |
10K |
2 |
23/02/17 |
23/02/17 |
ASX - By Stock
|
36
|
10K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Initial Director's Interest Notice
|
|
reader1
|
36 |
10K |
3 |
23/02/17 |
23/02/17 |
ASX - By Stock
|
36
|
10K
|
3
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Initial Director's Interest Notice
|
|
reader1
|
36 |
10K |
14 |
23/02/17 |
23/02/17 |
ASX - By Stock
|
36
|
10K
|
14
|
|
ASX - By Stock
|
VFX |
Re:
Ann: Appendix 4C - quarterly
|
|
reader1
|
25 |
6.7K |
2 |
02/02/17 |
02/02/17 |
ASX - By Stock
|
25
|
6.7K
|
2
|
|
ASX - By Stock
|
VFX |
Re:
Ann: Appendix 4C - quarterly
|
|
reader1
|
25 |
6.7K |
1 |
02/02/17 |
02/02/17 |
ASX - By Stock
|
25
|
6.7K
|
1
|
|
ASX - By Stock
|
VFX |
Re:
Ann: Appendix 4C - quarterly
|
|
reader1
|
25 |
6.7K |
6 |
01/02/17 |
01/02/17 |
ASX - By Stock
|
25
|
6.7K
|
6
|
|
ASX - By Stock
|
TSO |
Re:
Ann: Quarterly Update and Appendix 4C
|
|
reader1
|
2 |
1.0K |
1 |
01/02/17 |
01/02/17 |
ASX - By Stock
|
2
|
1.0K
|
1
|
|
ASX - By Stock
|
TSO |
Re:
Ann: Managing Director Remuneration and Board Changes
|
|
reader1
|
4 |
2.2K |
0 |
03/01/17 |
03/01/17 |
ASX - By Stock
|
4
|
2.2K
|
0
|
|
ASX - By Stock
|
TRI |
Re:
Ann: Excellent performance in the pilot phase of US Validation
|
|
reader1
|
14 |
4.8K |
11 |
23/12/16 |
23/12/16 |
ASX - By Stock
|
14
|
4.8K
|
11
|
|
ASX - By Stock
|
VFX |
Re:
Ann: 1ST signs largest subscription deal to date
|
|
reader1
|
6 |
2.0K |
0 |
22/12/16 |
22/12/16 |
ASX - By Stock
|
6
|
2.0K
|
0
|
|
ASX - By Stock
|
1AD |
Re:
Interesting looking stock
|
|
reader1
|
28 |
22K |
0 |
22/12/16 |
22/12/16 |
ASX - By Stock
|
28
|
22K
|
0
|
|
ASX - By Stock
|
VFX |
Re:
Ann: 1ST signs largest subscription deal to date
|
|
reader1
|
6 |
2.0K |
3 |
22/12/16 |
22/12/16 |
ASX - By Stock
|
6
|
2.0K
|
3
|
|
ASX - By Stock
|
TSO |
Re:
Ann: Sales and Operations Update
|
|
reader1
|
8 |
3.9K |
0 |
19/12/16 |
19/12/16 |
ASX - By Stock
|
8
|
3.9K
|
0
|
|
ASX - By Stock
|
TSO |
Re:
Ann: Sales and Operations Update
|
|
reader1
|
8 |
3.9K |
2 |
19/12/16 |
19/12/16 |
ASX - By Stock
|
8
|
3.9K
|
2
|
|
ASX - By Stock
|
TSO |
Re:
Ann: Plukka Performance Update
|
|
reader1
|
5 |
1.8K |
1 |
13/12/16 |
13/12/16 |
ASX - By Stock
|
5
|
1.8K
|
1
|
|
ASX - By Stock
|
TSO |
Re:
Ann: Results of Annual General Meeting
|
|
reader1
|
1 |
724 |
0 |
02/12/16 |
02/12/16 |
ASX - By Stock
|
1
|
724
|
0
|
|
ASX - By Stock
|
TSO |
Re:
Ann: Quarterly Update and Appendix 4C-PKA.AX
|
|
reader1
|
2 |
1.4K |
1 |
01/11/16 |
01/11/16 |
ASX - By Stock
|
2
|
1.4K
|
1
|
|
ASX - By Stock
|
TSO |
Re:
Ann: Resignation of Creative Director (App 3Z)-PKA.AX
|
|
reader1
|
2 |
1.2K |
0 |
05/09/16 |
05/09/16 |
ASX - By Stock
|
2
|
1.2K
|
0
|
|
ASX - By Stock
|
TSO |
Re:
Waiting for the punchline
|
|
reader1
|
11 |
3.2K |
0 |
19/08/16 |
19/08/16 |
ASX - By Stock
|
11
|
3.2K
|
0
|
|
ASX - By Stock
|
TSO |
Re:
Waiting for the punchline
|
|
reader1
|
11 |
3.2K |
0 |
19/08/16 |
19/08/16 |
ASX - By Stock
|
11
|
3.2K
|
0
|
|
ASX - By Stock
|
TSO |
Waiting for the punchline
|
|
reader1
|
11 |
3.2K |
0 |
19/08/16 |
19/08/16 |
ASX - By Stock
|
11
|
3.2K
|
0
|
|
ASX - By Stock
|
APX |
Re:
Bell Potter raises target
|
|
reader1
|
17 |
11K |
1 |
09/06/16 |
09/06/16 |
ASX - By Stock
|
17
|
11K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Australian Cardiac Surgeons
|
|
reader1
|
82 |
20K |
3 |
16/05/16 |
16/05/16 |
ASX - By Stock
|
82
|
20K
|
3
|
|
ASX - By Stock
|
AVR |
Re:
Australian Cardiac Surgeons
|
|
reader1
|
82 |
20K |
2 |
16/05/16 |
16/05/16 |
ASX - By Stock
|
82
|
20K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Australian Cardiac Surgeons
|
|
reader1
|
82 |
20K |
3 |
16/05/16 |
16/05/16 |
ASX - By Stock
|
82
|
20K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Results of Phase 2 trial in moderate to severe TBI-NEU.AX
|
|
reader1
|
86 |
38K |
2 |
28/04/16 |
28/04/16 |
ASX - By Stock
|
86
|
38K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Results of Phase 2 trial in moderate to severe TBI-NEU.AX
|
|
reader1
|
86 |
38K |
0 |
28/04/16 |
28/04/16 |
ASX - By Stock
|
86
|
38K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Results of Phase 2 trial in moderate to severe TBI-NEU.AX
|
|
reader1
|
86 |
38K |
5 |
28/04/16 |
28/04/16 |
ASX - By Stock
|
86
|
38K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Results of Phase 2 trial in moderate to severe TBI-NEU.AX
|
|
reader1
|
86 |
38K |
3 |
26/04/16 |
26/04/16 |
ASX - By Stock
|
86
|
38K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Results of Phase 2 trial in moderate to severe TBI-NEU.AX
|
|
reader1
|
86 |
38K |
3 |
26/04/16 |
26/04/16 |
ASX - By Stock
|
86
|
38K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Results of Phase 2 trial in moderate to severe TBI-NEU.AX
|
|
reader1
|
86 |
38K |
0 |
26/04/16 |
26/04/16 |
ASX - By Stock
|
86
|
38K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Results of Phase 2 trial in moderate to severe TBI-NEU.AX
|
|
reader1
|
86 |
38K |
4 |
26/04/16 |
26/04/16 |
ASX - By Stock
|
86
|
38K
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Results of Phase 2 trial in moderate to severe TBI-NEU.AX
|
|
reader1
|
86 |
38K |
0 |
26/04/16 |
26/04/16 |
ASX - By Stock
|
86
|
38K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Results of Phase 2 trial in moderate to severe TBI-NEU.AX
|
|
reader1
|
86 |
38K |
1 |
26/04/16 |
26/04/16 |
ASX - By Stock
|
86
|
38K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Results of Phase 2 trial in moderate to severe TBI-NEU.AX
|
|
reader1
|
86 |
38K |
4 |
26/04/16 |
26/04/16 |
ASX - By Stock
|
86
|
38K
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Share price today
|
|
reader1
|
23 |
9.5K |
2 |
26/04/16 |
26/04/16 |
ASX - By Stock
|
23
|
9.5K
|
2
|
|
ASX - By Stock
|
WSA |
Re:
Ann: Western Areas Announces Placement and SPP
|
|
reader1
|
7 |
2.4K |
3 |
01/04/16 |
01/04/16 |
ASX - By Stock
|
7
|
2.4K
|
3
|
|